D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, their new medicine development approach is fundamentally differentiated.  They do not just only start with science in the lab. First, they pinpoint the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then they take those insights into lab to guide the identification of fit for purpose science and technology, and define their drug development path.  

D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Their portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio.  In fact, it underlies their name: Development leading to Discovery that then leads back to more Development, or D3 Bio.”

D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.

Biotechnology

D3 Bio

George Chen

Zhiqiang Chen

成 陈

Allison Wang

John Jin

D3 Bio's CEO and Executive Team includes George Chen.

CEO and Executive Team

Board of Directors

Founding Team

CEO and Executive Team

About

Team members

Other teams at D3 Bio

Board of Directors

Founding Team